The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | An insight into the future treatment landscape of CLL
Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, shares some insights into the future of chronic lymphocytic leukemia (CLL) treatment, drawing focus on novel drug combinations. Dr Efremov first explains the excitement surrounding novel agents that function by blocking microenvironmental signals, such as Bruton’s tyrosine kinase (BTK) inhibitors. Dr Efremov then highlights the importance of further investigating combinations with the BCL-2 inhibitor venetoclax, which may allow for deeper clinical responses and improved outcomes for patients with CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
